Results 41 to 50 of about 25,204 (165)
Expanding the clinical uses of ctDNA
Practical oncology, 2021 The majority of currently available studies on the use of this circulating tumour DNA (ctDNA) deal with the detection of mutations. The analysis of cfDNA is often discussed in the context of the noninvasive detection of mutations that lead to resistance mechanisms and therapeutic and disease monitoring in cancer patients.
openaire +1 more source
Advances in Laboratory MedicineEpidermal growth factor receptor gene (EGFR) molecular testing is essential for guiding targeted therapies in patients with advanced non-small cell lung cancer (NSCLC). Between 15 and 40 % of patients with NSCLC carry mutations in EGFR that are sensitive
Fernández-Galán Esther +1 more
doaj +1 more source
Advances in Clinical Application of ctDNA in Tumor Detection, Screening, Prognosis and Treatment
Zhongliu Fangzhi Yanjiu, 2020 Circulating tumor DNA (ctDNA) is a tumor-derived fragmented DNA in blood and is a characteristic marker of tumor. Through the correlative detection of ctDNA, the trace information of the tumor in the blood of the patients can be detected, and the ...
LIU Yong
doaj +1 more source
Cancer Management and Research, 2021 Shaohua Guo,1,2,* Yumeng Ye,3,* Xinyi Liu,4 Yuan Gong,5 Mingyan Xu,4 Lele Song,4,6 Hongyi Liu1 1Department of General Surgery, The First Medical Center of the Chinese PLA General Hospital, Beijing, People’s Republic of China; 2Department of ...
Guo S +6 more
doaj
Journal of Laboratory MedicineCirculating tumor DNA (ctDNA) assays play an increasingly important role in cancer management. A new version of TruSight Oncology 500 (TSO500) ctDNA, v2, was recently released, and the recommended DNA input was decreased to 20 ng from 30 ng in the prior ...
Lee Cheonghwa +3 more
doaj +1 more source
Response-adaptive breast cancer care in the grey zones: integrating ER and HER2 targeted PET, FDG PET/CT under immunotherapy, and ctDNA kinetics [PDF]
Exploration of Targeted Anti-tumor TherapyBreast cancer management increasingly hinges on decisions made in “grey zones” where tissue sampling is scarce, and tumour biology evolves under therapeutic pressure.
Jovana Zivanovic, Jules Zhang-Yin
doaj +1 more source
ctDNA in Pancreatic Adenocarcinoma: A Critical Appraisal
Current OncologyPancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignancies due to late diagnosis and limited treatment options. Circulating tumor DNA (ctDNA) is a promising, minimally invasive biomarker that could improve the clinical outcomes of patients with PDAC by enabling early disease detection, minimal residual disease (MRD) assessment ...
Ojha, Sujata +3 more
openaire +2 more sources
Detection of Hypomethylation in Long-ctDNA
Clinical Chemistry, 2022 Simon A Joosse, Klaus Pantel
openaire +2 more sources
Dynamics of ctDNA in patients with NSCLC
Annals of Oncology, 2019 Abstract Background For many years, researchers have tried to find more effective ways to find out if a person has cancer, and find it at an early stage, when it is most curable. One idea that is gaining popularity is called liquid biopsy. Methods From 2016 to 2018 we studied 1050 patients with non-small-cell lung cancer (NSCLC).
A.S. Zhabina +4 more
openaire +1 more source
Contemporary Use of ctDNA for the Colorectal Surgeon
Clinics in Colon and Rectal SurgeryAbstractWhile advances in treatment and diagnostics have improved prognosis in colorectal cancer (CRC), room for advancement remains, highlighting the importance of improving tools for early detection and treatment guidance. Current national guidelines rely on stage-based treatment recommendations but fail to identify patients with lower stage disease ...
Heit, Madilyn, Cohen, Stacey A.
openaire +2 more sources